Back to discover
Drug

Ozone

In clinical development
Emerging researchLate-stage development

Also known as ozono.

2
Research papers
3
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

CXCL10/CXCR3 Regulation of Ozone-Induced Epithelial Permeability

Clinical trial2026-06-15Results posted · ClinicalTrials.gov

Mechanisms of Ozone-Induced Alterations in Efferocytosis and Phagocytosis

Clinical trial2026-06-15Results posted · ClinicalTrials.gov

Macrophage Regulation of Ozone-Induced Lung Inflammation

Clinical trial2026-05-15Results expected Q2 2028 · ClinicalTrials.gov

Ozone Pollution: A Major Health Hazard Worldwide.

Research2019-10-31Frontiers in immunology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ozone
Aliases & brands
ozono
RxNorm CUI
2289011
ChEMBL ID
CHEMBL2447938
UNII
66H7ZZK23N

Clinical trials

23 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
23
registered trials across all phases
LATEST COMPLETION 2025
3
Active studies
3
Recruiting
17
Late-stage (III+)
12
Completed
8
Discontinued
PHASE DISTRIBUTIONn = 23
Early Phase 11Phase 13Phase 22Phase 2 / 33Phase 32Phase 42Phase N / A10

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192020
Major research themes3
Air Microbiology1Air Pollution1Global Health1
Journals, researchers & institutions
Top journals
  • Frontiers in immunology1
  • PloS one1
Leading researchers
  • Dubuis ME1
  • Duchaine C1
  • Dumont-Leblond N1
  • Fang Z1
  • Jean J1
  • Laliberté C1
  • Turgeon N1
  • Veillette M1
Leading institutions
free-text, unnormalised
  • Center for Global Health1
  • Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval1
  • Global Health Research Center1
  • Guangzhou Institute of Respiratory Health1
  • Nicholas School of the Environment and Duke Global Health Institute1
  • State Key Laboratory of Environmental Criteria and Risk Assessment & Environmental Standards Institute1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials